Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma: Petrarca—A phase II trial of the German AIO.Ralf‐Dieter Hofheinz, Salah‐Eddin Al‐Batran, Michael Koenigsmann et al.|Journal of Clinical Oncology|2017Cited by 12
Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades of the German AIO study groupLena Weiss, Michael Haas, Laura Fischer et al.|ESMO Open|2024Cited by 3
Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?Lena Weiss, Michael Haas, Volker Heinemann et al.|Clinical & Translational Oncology|2023Cited by 2